These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 35503226)

  • 1. Targeting SHP2 phosphatase in hematological malignancies.
    Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
    Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
    Song Y; Zhao M; Zhang H; Yu B
    Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
    Tang K; Jia YN; Yu B; Liu HM
    Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
    Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
    J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHP2 sails from physiology to pathology.
    Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
    Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Biological Function of SHP2 in Human Disease].
    Li SM
    Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
    Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
    Elife; 2022 May; 11():. PubMed ID: 35535491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
    Wu J; Zhang H; Zhao G; Wang R
    Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of SHP2 as an approach to block RAS-driven cancers.
    Chou YT; Bivona TG
    Adv Cancer Res; 2022; 153():205-236. PubMed ID: 35101231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
    Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A patent review of SHP2 allosteric inhibitors (2018-present).
    Petrocchi A; Ciammaichella A
    Expert Opin Ther Pat; 2024 May; 34(5):383-396. PubMed ID: 38842843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine phosphatase Shp2 in development and cancer.
    Grossmann KS; Rosário M; Birchmeier C; Birchmeier W
    Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
    Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Tyrosine Phosphatase Non-Receptor 11 (
    Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
    [No Abstract]   [Full Text] [Related]  

  • 20. Functions of Shp2 in cancer.
    Zhang J; Zhang F; Niu R
    J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.